Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The attention deficit hyperactivity disorder (ADHD) treatment market was valued at USD 14.64 billion in 2023, driven by heightened awareness of ADHD among people across the 8 major markets. The market is expected to grow at a CAGR of 5.1% during the forecast period of 2024-2032, with values likely to reach USD 22.91 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Attention deficit hyperactivity disorder (ADHD) is a brain disorder which hampers the ability of a person to pay attention to things, along with behaviour control. It is among the most common brain disorders diagnosed in children. Both children and adults are affected by the condition, however, it is commonly diagnosed in children which further continues to adulthood.
Rising Incidence of the Disease
The increasing rates of ADHD diagnoses are highly contributing to the increased demand for ADHD treatment. However, the reason behind the heightening number of ADHD diagnoses is the increasing recognition of the condition. Parents are paying more attention to their children, therefore, the diagnosis rate of the condition is rising. As per the report published by the Centers for Disease Control and Prevention in May 2024, 1 in every 9 children in the United States between the age of 3-17 have been diagnosed with attention deficit hyperactivity disorder (ADHD).
Additionally, in 2022, a report by the American public broadcasting organization revealed that nearly 7.1 million people (including kids) were diagnosed with ADHD.
Additionally, the window of treatment for children suffering from ADHD is also wide open, as it was also found by the study that the total number of children taking medications was only half the number of children diagnosed with ADHD. This highlights a wide gap of unmet actions and initiatives to spread the awareness about the condition, propelling the possibilities of market expansion.
Adoption of Novel Therapeutics
As the healthcare domain is witnessing instrumental strides towards technological advancements, the ADHD treatment market is also influenced. The market players like Akili are coming to the forefront and establishing a new benchmark in the ADHD treatment market. Akili Interactive, a prescription-based digital medicine company announced the 510k clearance of its phone-based video game in June 2024. The game is curated and designed to manage attention-deficit hyperactivity disorder (ADHD). As the first-ever video game for ADHD management, it showcased notable efficacy of 83% clinical response in clinical trials. Such innovations have great potential in improving patient health as well as create huge market demand and support the upward trajectory of the market in the forecast period.
Surge in Drug Approvals to Meet Rising Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market Demand
With increasing awareness, the diagnoses incidence is collectively booming. The market value is further fuelled by the escalating number of drug approvals for effective management of the disease. In May 2024, the US Food and Drug Administration (FDA) gave a nod to Tris Pharma’s Onyda XR (clonidine hydrochloride) indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The drug is the first ever and only liquid stimulant ADHD medication receiving FDA approval in the United States. It is a once-a-day extended-release oral suspension with nighttime dosing indicated as a monotherapy for pediatric patients 6 years and older. Such drug approvals by the regulatory authorities are anticipated to propel market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Key Trends | Impact |
Increasing Awareness of ADHD | There is a significant increase in the awareness about attention deficit hyperactivity disorder (ADHD) among people which is a major reason that people are coming forward to avail dedicated treatments. |
Increasing Diagnosis Rates | The rising incidence of ADHD diagnosis can be attributed to heightened awareness. The application of new technologies to detect the condition at an early age is amongst the major market trends. |
Improved Medication and Treatment | The market is experiencing a rise in research activities by institutions and healthcare facilities to interpret the condition better and analyse symptoms, helpful in developing improved medication and personalised treatment for patients. |
Campaigns and Initiatives | The governments are taking several initiatives to increase the awareness of ADHD among people. It involves partnerships with non-profit organisations and academic institutions to launch campaigns and boost awareness about the condition. For instance, NHS England has proposed to launch a new attention deficit hyperactivity disorder (ADHD) taskforce in collaboration with the government to improve care for ADHD people. |
Market Breakup by Treatment Type
Market Breakup by Age Group
Market Breakup by Gender
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Treatment Type to Witness Substantial Growth
The market segmentation based on treatment type is broadly segmented into stimulants and non-stimulants. Stimulants are further divided into Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate and Lisdexamfetamine Dimesylate, whereas, non-stimulants include Atomoxetine, Bupropion, Guanfacine and Clonidine. The stimulants are expected to dominate the market segment as they are highly effective in managing ADHD among both children and adults. Stimulants are commonly preferred by medical professionals due to their proven efficacy in treating the condition and improving patient outcomes.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on region, the market report offers insights for the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India.
In the market segmentation based on region, the United States has the largest market share due to the rising incidence of the condition. The market share is also influenced by the heightened level of awareness among people about the ADHD condition. According to the data released by the U.S Centers for Disease Control and Prevention, 56.9% of children aged between 6-11 years, are currently receiving ADHD treatments.
The key features of the market report comprise clinical trial analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Takeda Pharmaceutical Company Limited
Headquartered in Tokyo, Japan, Takeda is a multinational pharmaceutical company. It is the third-largest pharmaceutical company in Asia. The company offers plasma-derived treatment therapies and vaccines focused on medical conditions such as oncology, rare diseases, neuroscience, and gastroenterology.
Aytu BioPharma, Inc.
Aytu BioPharma, Inc. headquartered in Denver, Colorado, is a dynamic speciality pharmaceutical company with an expanding portfolio of prescriptions primarily focused on complex conditions such as ADHD and other common conditions.
Eli Lilly and Company
Headquartered in Indiana, United States, Eli Lily and Company is a pharmaceutical company with an expanding foot reach in more than 125 countries. With primary drug offerings for conditions like diabetes, the company is also known for its clinical depression drugs like Prozac.
Pfizer Inc.
Headquartered in Manhattan, New York, Pfizer is a multinational pharmaceutical and biotechnology corporation. The company offers drugs and vaccines for the treatment of conditions such as immunology, oncology, cardiology, endocrinology, and neurology.
Other key players in the market include Noven Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Novartis AG, Curemark, LLC, Highland Therapeutics Inc., and GlaxoSmithKline Plc.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Treatment Type |
|
Breakup by Age Group |
|
Breakup by Gender |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share